---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-246775"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:46:01.390741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track

## Summary
- Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.
- Cash, equivalents and short-term investments totaled $715M as of Sept 30, 2025, down from $903M at Dec 31, 2024.
- Phase 3 VANQUISH-1 for VK2735 in obesity expects enrollment completion by end of 2025; VANQUISH-2 by Q1 2026.
- Phase 2 VENTURE-Oral study showed up to 12.2% mean weight loss after 13 weeks; up to 97% achieved ≥5% weight loss.
- Maintenance dosing study of VK2735 initiated; plans to file IND for dual amylin/calcitonin agonist in Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-246775
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/0001193125-25-246775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/vktx-20251022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-246775
- JSON: https://secwatch.observer/filing/0001193125-25-246775.json
- Plain text: https://secwatch.observer/filing/0001193125-25-246775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.